Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hi! Today, we discuss why an advisory committee was not thrilled with Amgen’s data for Lumakras, and Neurocrine Biosciences has a potential blockbuster up its sleeve. Oh, and we’ll be off for Indigenous Peoples’ Day next week and will be back in your inbox Tuesday!


The need-to-know this morning
• Sanofi is exploring an acquisition of Mirati Therapeutics, Bloomberg reported, news that sent the company’s share price up nearly 50%.

Get unlimited access to award-winning journalism and exclusive events.


Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!

To submit a correction request, please visit our Contact Us page.